<u>ISS GVS PHARMA LTD.</u>



May 14, 2022

To

The Manager, Listing Department

National Stock Exchange of India Limited

Plot no. C/1 G Block,

Bandra-Kurla Complex, Bandra (East),

Mumbai-400 051

Symbol: BLISSGVS

To

The General Manager, Listing Department

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai- 400 001

Scrip Code: 506197

Subject: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed herewith the disclosure of Related Party Transactions for the period from October 01, 2021 to March 31, 2022.

Kindly take the same on your record.

Thanking you,

Yours faithfully,

For Bliss GVS Pharma Limited

Aditi Bhatt

Company Secretary

Encl: as above

Regd. Office: 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL.: (+91) (22) 42160000/ 28505387 • FAX.: (+91) (22) 28563930,

Email: info@blissgvs.com • Website: www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory: Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.

Tel. (+91) (02525) 252713 • Fax: (+91) (02525) 255257. • Email: factory@blissgvs.com

	Details of	Details of	ab. a	Type of	Value of the	Value of	In case moi	iaa aya dua	relate invest to be was u	ed party tments r	transaction made or give ed only once en.	relates to lo en by the list , during the	ans, inter-c ed entity/s reporting p	ns - applicablo orporate dep ubsidiary. Th eriod when s	oosits, adva ese details such transac	nces or need ction
S. No.	the party (listed entity /subsidiary) entering into the transaction	counterparty ted bsidiary) cering to the		arty related party related party transactio to e transaction transaction as n during resu		to either party as a result of the transaction (see Note 1)		indebtedness is incurred to make or give loans, intercorporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments					
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nat ure of inde bte dne ss (loa n/ issu anc e of deb t/ any oth er etc.	Cost (see Note 7)	Tenure	Nature (loan/ advance/ inter- corporat e deposit/ investme nt	Interest Rate (%)	Tenure	Secure d/ Unsecu red	Purp ose for whic h the fund s will be utilis ed by the ultim ate recip ient of fund s (end - usag e)

1.	Bliss GVS Pharma Limited	Mr. S. N. Kamath	Promoter and Relative of Director (from 12-5- 21)	Payment of Rent	As Approved by Audit Committee	55.00	-	-	-	-	-	1	-	-	-	-
2	Bliss GVS Pharma Limited	Mr. S. N. Kamath	Promoter and Relative of Director (from 12-5- 21)	Refundable deposit for Leave License	As Approved by Audit Committee	-	78.75	78.75	-	-	-	-	-	-	-	-
3	Bliss GVS Pharma Limited	Mr. S. N. Kamath	Promoter and Relative of Director (from 12-5- 21)	Reimburseme nt of Expenses	As Approved by Audit Committee	0.86	-	-	-	-	-	-	-	-	-	-
4.	Bliss GVS Pharma Limited	Geeta N. Kamath	Relative of Director (from 12-5- 21)	Payment of Rent	As Approved by Audit Committee	1.97	-	-	-	-	-	-	-	-	-	-
5.	Bliss GVS Pharma Limited	Mrs. Shruti Vishal Rao	Director	Remuneration	As approved by Nomination & Remuneration Committee/Audit Committee/Board	30.47	-	-	-	-	-	-	-	-	-	-
6.	Bliss GVS Pharma Limited	Dr. Vibha Gagan Sharma	Director	Remuneration	As approved by Nomination & Remuneration Committee/Audit Committee/Board	30.47	-	-	-	-	-	-	-	-	-	-
7.	Bliss GVS Pharma Limited	Mr. Gagan Harsh Sharma	Managing Director	Remuneration	As approved by Nomination & Remuneration Committee/Audit Committee/Board	77.66	-	-	-	-	-	-	-	-	-	-
8.	Bliss GVS Pharma Limited	Mr. Vishal Rao	Relative of Director	Remuneration	As approved by Nomination & Remuneration Committee/Audit Committee/Board	30.84	-	-	-	-	-	-	-	-	-	-
9.	Bliss GVS Pharma Limited	Mr. Vipul B. Thakkar	Key management personnel of	Remuneration	As approved by Nomination & Remuneration	38.74	-	-	-	-	-	-	-	-	-	-

			entity or parent		Committee/Audit Committee/Board											
10.	Bliss GVS Pharma Limited	Ms. Aditi Bhatt	Key management personnel of entity or parent	Remuneration	As approved by Nomination & Remuneration Committee/Audit Committee/Board	6.33	-	-	-	-	-	-	-	-	-	-
11.	Bliss GVS Pharma Limited	Bliss GVS Internati onal Pte Ltd	Wholly Owned Subsidiary	Investment in Share Capital	NA	-	22.58	22.58	-	-	-	Investme nt in equity	NA	NA	Unsecu red	Inves tme nt mad e for busi ness purp ose
12.	Bliss GVS Pharma Limited	Bliss GVS Internati onal Pte Ltd	Wholly Owned Subsidiary	Interest Income/ Receivable	As Approved by Audit Committee	151.63	372.46	507.42	-	-	-	-	-	-	-	
13.	Bliss GVS Pharma Limited	Bliss GVS Internati onal Pte Ltd	Wholly Owned Subsidiary	Loan Given	As Approved by Audit Committee	3,660.42	4,267.20	8,070.93	-	-	-	Loan	4.5%	Repayable on Demand	Unsecu red	Loan utilis ed for busi ness
14.	Bliss GVS Pharma Limited	Kremoint Pharma Pvt ltd	Subsidiary	Labour Charges and purchases of goods	As Approved by Audit Committee	22.58	-	-	-	-	1	1	1	-	-	-
15.	Bliss GVS Pharma Limited	Kremoint Pharma Pvt ltd	Subsidiary	Investment in Share Capital	NA	-	1,803.00	1,803.00	-	-	-	Investme nt in equity	NA	NA	Unsecu red	Inves tme nt mad e for busi ness purp ose
16.	Bliss GVS Pharma Limited	Kremoint Pharma Pvt ltd	Subsidiary	Paid/Trade Payables	As Approved by Audit Committee	36.93	12.20	0.16	-	-	ı	-	-	-	-	-

17.	Bliss GVS Pharma Limited	Kremoint Pharma Pvt ltd	Subsidiary	Received/Tra de Receivable	As Approved by Audit Committee	63.26	21.78	61.98	-	-	-	-	-	-	-	-
18.	Bliss GVS Pharma Limited	Kremoint Pharma Pvt ltd	Subsidiary	Sale of Goods	As Approved by Audit Committee	98.91	-	-	-	1	-	-	-	-	-	-
19.	Bliss GVS Pharma Limited	Bliss GVS Clinics Health Care Pte Ltd	Wholly Owned Subsidiary	Investment in Share capital	NA	-	4.12	-	-	-	-	Investme nt in equity	NA	NA	Unsecu red	Inves tme nt mad e for busi ness purp ose
20.	Bliss GVS Pharma Limited	Bliss GVS Clinics Health Care Pte Ltd	Wholly Owned Subsidiary	Disinvestment in Shares	As Approved by Audit Committee and Board	4.12	-	-	-	-	-	-	-	-	-	-
21.	Bliss GVS Pharma Limited	Bliss GVS Clinics Health Care Pte Ltd	Wholly Owned Subsidiary	Loan Given	As Approved by Audit Committee	-	3,007.33	-	-	-	-	Loan	4.5%	Repayable on Demand	Unsecu red	Loan utilis ed for busi ness
22.	Bliss GVS Pharma Limited	Bliss GVS Clinics Health Care Pte Ltd	Wholly Owned Subsidiary	Loan Repaid	As Approved by Audit Committee	3,058.48	-	-	-	-	-	-	-	-	-	-
23.	Bliss GVS Pharma Limited	Bliss GVS Clinics Health Care Pte Ltd	Wholly Owned Subsidiary	Interest receivable	As Approved by Audit Committee	25.54	595.30	0	-	-	-	-	-	-	-	-
24.	Bliss GVS Pharma Limited	Bliss GVS Clinics Health Care Pte Ltd	Wholly owned Subsidiary	Interest received	As Approved by Audit Committee	638.97	-	-	-	-	-	-	-	-	-	-

25.	Bliss GVS Pharma	Asterisk Lifescien	Wholly Owned	Investment In Share Capital	As Approved by Audit Committee	-	0.10	0.10	-	-	-	Investme nt in	NA	NA	Unsecu red	Inves
	Limited	ces Limited (UK)	Subsidiary	знате Саріса	Addit Committee		0.10	0.10				equity			Teu	tme nt mad e for
																busi ness purp ose
26.	Bliss GVS Pharma Limited	Asterisk Lifescien ces Limited (UK)	Wholly Owned Subsidiary	Loan Given	As Approved by Audit Committee	-	19.86	19.80	-	-	-	Loan	4.5%	Repayable on Demand	Unsecu red	Loan utilis ed for busi ness
27.	Bliss GVS Pharma Limited	Asterisk Lifescien ces Limited (UK)	Wholly Owned Subsidiary	Interest Received/Rec eivable	As Approved by Audit Committee	0.44	2.06	2.50	-	-	-	-	-	-	-	-
28.	Bliss GVS Pharma Limited	Asterisk Lifescien ces Limited (UK)	Wholly Owned Subsidiary	Trade Receivable	As Approved by Audit Committee	-	17.29	16.99	-	-	-	-	-	-	-	-
29.	Bliss GVS Pharma Limited	Asterisk Lifescien ces GH Limited	Step-down Subsidiary	Received/Tra de Receivables	As Approved by Audit Committee	2,620.37	4,766.60	7,360.55	-	-	-	-	-	-	-	-
30.	Bliss GVS Pharma Limited	Asterisk Lifescien ces GH Limited	Step-down Subsidiary	Reimburseme nt of Expenses received	As Approved by Audit Committee	14.80	-	-	-	-	-	-	-	-	-	-
31.	Bliss GVS Pharma Limited	Asterisk Lifescien ces GH Limited	Step-down Subsidiary	Sale of Goods	As Approved by Audit Committee	5,091.28	-	-	-	-	-	-	-	-	-	-
32.	Bliss GVS Pharma Limited	Greenlife Bliss Healthca re	Step-down Subsidiary	Trade Receivables	As Approved by Audit Committee	-	11.23	11.46	-	-	-	-	-	-	-	-

33.	Bliss GVS Pharma Limited	Bliss GVS Charitabl e Trust	Enterprise over which KMP exercises significant influence	Donation	As Approved by Audit Committee	20.00	-	-	-	-	-	-	-	-	-	-
Total (of Note 6b)						15780.07										

Note: Foreign balances are reinstated wherever applicable

Notes:

- 1. The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.
- 2. Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be reported once.
- 3. Listed banks shall not be required to provide the disclosures with respect to related party transactions involving loans, inter-corporate deposits, advances or investments made or given by the listed banks.
- 4. For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31. Companies with financial years ending in other months, the six months period shall apply accordingly.
- 5. Each type of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transactions of same type. However, transactions with the same counterparty of the same type may be aggregated for the reporting period. For instance, sale transactions with the same party may be aggregated for the reporting period and purchase transactions may also be disclosed in a similar manner. There should be no netting off for sale and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed separately, without any netting off.
- 6. In case of a multi-year related party transaction:
- a. The aggregate value of such related party transaction as approved by the audit committee shall be disclosed in the column "Value of the related party transaction as approved by the audit committee".
- b. The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reporting period".
- 7. "Cost" refers to the cost of borrowed funds for the listed entity.
- 8. PAN will not be displayed on the website of the Stock Exchange(s).
- 9. Transactions such as acceptance of fixed deposits by banks/NBFCs, undertaken with related parties, at the terms uniformly applicable /offered to all shareholders/ public shall also be reported.